研究单位:[1]AbbVie[2]University of Arizona Cancer Center[3]VA Central California Health Care System[4]Union Hospital Tongji Medical College Huazhong University of Science and Technol
A study designed to evaluate the safety and efficacy of venetoclax plus dexamethasone (VenDex) compared with pomalidomide plus dexamethasone (PomDex) in participants with t(11;14)-positive Relapsed or Refractory Multiple Myeloma.